Dermatology is shifting from surface-level cosmetics to biology-driven interventions targeting aging hallmarks, with senolytics, epigenetic reprogramming, and biomimetic peptides leading the charge. D...
Phase 1 data for BGE-102 demonstrates significant reductions in hsCRP and inflammatory biomarkers, positioning it as a potential best-in-class therapy for cardiovascular risk and age-related inflammat...
Life Biosciences launches a Phase I trial for cellular reprogramming to treat age-related macular degeneration, challenging aging norms with FDA’s Plausible Mechanism Pathway, amid rising invest...
uPAR-targeted CAR T cell therapy shows promising results in solid tumors, with recent clinical trials and FDA designations advancing cancer immunotherapy towards precision medicine. Recent advancement...
Muscle-generated exerkines in extracellular vesicles are crucial for exercise-induced health, with new research suggesting therapies for sarcopenia and metabolic diseases through inter-organ communica...
New research shows that enzyme Pck1 depletion drives senescence in fat cells, causing insulin resistance and inflammaging, highlighting it as a promising target for age-related metabolic diseases. A r...
Recent studies show encapsulated mitochondria delivery using red blood cell membranes improves motor function and neuron survival in Parkinson’s disease models, offering hope for mitochondrial d...
Senolytic and senomorphic therapies, including Rubedo’s RLS-1496 in Phase 1 trials, target senescent cells to treat aging diseases, boosted by AI-driven discovery and rising investment. New seno...
Recent breakthroughs in senolytic and senomorphic therapies, including polyunsaturated lipids inducing ferroptosis, are advancing clinical trials for age-related diseases, with a focus on safety and b...
Recent studies reveal MG53 (TRIM72) enhances muscle stem cell activation and reduces inflammation, offering a novel therapeutic target for sarcopenia with promising preclinical and early clinical resu...
